Top 10 Owners of Sesen Bio Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 6.27% | 12,501,509 |
| The Vanguard Group, Inc. | 5.99% | 11,951,290 |
| Geode Capital Management LLC | 2.26% | 4,511,761 |
| SSgA Funds Management, Inc. | 2.15% | 4,286,758 |
Similarly, What does Sesen Bio do?
At Sesen Bio, we are committed to saving and improving the lives of patients with cancer. We are a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer.
Will Vicinium get approved? The FDA has issued a complete response letter to Sesen Bio, denying the approval of the Biologics License Application for Vicinium for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.
Thereof, Who owns sesen bio?
Major institutions are defined as firms or individuals that exercise investment discretion, over the assets of others, in excess of $100 Million.
…
New and Sold Out Positions.
| OWNER NAME | SUSQUEHANNA INTERNATIONAL GROUP, LLP |
|---|---|
| SHARES HELD | 642,553 |
| CHANGE (SHARES) | -53,619 |
| CHANGE (%) | -7.702% |
| VALUE (IN 1,000S) | $366 |
What is Vicinium?
Vicinium is a single protein drug consisting of an Epithelial Cell Adhesion Molecule (EpCAM)-specific antibody fragment fused to a potent pseudomonas toxin. After intravesical instillation, Vicinium binds EpCAM, is internalized and kills tumor cells by inhibiting protein synthesis.
What is Adstiladrin?
Adstiladrin is given by catheter directly into the bladder. It consists of a type of virus that is able to introduce a gene into cells of the bladder. This gene then stimulates the cells of the bladder to produce high quantities of a protein that the body uses to fight cancer.
What is Instiladrin?
INSTILADRIN is a non-replicating adenovirus. vector harboring the human IFN alpha2b gene. When combined with the excipient Syn3, intravesical administration of the rAd-IFN results in transduction of the virus into the. epithelial cell lining in the bladder.
Why did sesen bio stock drop?
Sesen Bio (NASDAQ:SESN) has had a terrible few months after the FDA declined to approve Vicineum in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The stock dropped from a healthy $5 to below $1 at one point and is currently straggling on at $1.22.
How is Vicinium administered?
Induction – 30 mg of Vicinium in 50 mL of saline administered twice weekly (BIW) for 6 weeks followed by once weekly for 6 weeks, for a total of 12 weeks. Maintenance – 30 mg of Vicinium in 50 mL of saline administered once weekly every other week for up to 104 weeks.
What does BCG treat?
Bacillus Calmette-Guerin or BCG is the most common intravesical immunotherapy for treating early-stage bladder cancer. It’s used to help keep the cancer from growing and to help keep it from coming back. BCG is a germ that’s related to the one that causes tuberculosis (TB), but it doesn’t usually cause serious disease.
Is BCG better than chemo?
BCG is most commonly used in intravesical immunotherapy for NMIBC and appears to be more effective than intravesical chemotherapy in preventing tumor recurrence and progression. Especially for those with high-risk NMIBC, BCG immunotherapy is considered as a gold-standard treatment (29).
Is BCG available now?
A. Merck is the sole maker and supplier of BCG to the United States. While the FDA is exploring opportunities to approve additional strains and supplies of BCG, Merck is still the only approved supplier at this time. There are companies in Japan, Canada, and Europe working to develop their own strains of BCG.
How successful is BCG treatment?
A recent study was published evaluating maintenance BCG therapy [23]. The authors observed a three-year recurrence free survival of 75.3% and disease-free survival of 96.1%. However, they reported a high complication rate of 81.5%.
Is BCG better than mitomycin?
The overall analysis revealed a significant benefit of BCG compared with mitomycin C in terms of 5-year PFS rate (odds ratio, 0.53; 95% confidence interval, 0.38–0.75; P<0.001), indicating that BCG was superior to mitomycin C therapy in patients with non-muscle invasive bladder cancer following transurethral resection.
How many times can you have BCG treatments?
Maintenance BCG is typically given once per week for three weeks at 3, 6, and 12 months after the initial BCG treatment. In some cases, maintenance BCG treatment will be recommended for one year for those at intermediate risk of recurrence and for three years for those at higher risk for recurrence.
How long does BCG stay in your body?
BCG can remain in urine for 6 hours after your treatment, so each time you urinate, you should bleach the toilet in your home to neutralize the vaccine.
Is BCG available in USA?
Bacille Calmette-Guérin (BCG) is a vaccine for tuberculosis (TB) disease. This vaccine is not widely used in the United States, but it is often given to infants and small children in other countries where TB is common.
Who manufactures BCG vaccine?
2.1. BCG vaccine formulations
| BCG strain | Mother strain (year of derivation) | Manufacturer |
|---|---|---|
| BCG USA (Tice) | BCG Pasteur (1934) | Merck, USA |
• 24 févr. 2020
Why is BCG so hard to get?
There are several reasons for the shortage of BCG. The first is that there have been manufacturing restrictions placed on its production. Second, due to the slow growth of mycobacteria, BCG is extremely hard to make.
How long does BCG vaccine stay in your system?
BCG vaccination given to babies and young children provides consistent protection (up to 80%) against severe forms of childhood TB, such as TB meningitis. It can be less effective against TB affecting the lungs in adults. The protection from the BCG vaccine can last up to 15 years.
How much does a BCG treatment cost?
The mean cost of BCG therapy was US$1,936 per patient, and its cost-effectiveness ratio was US$525 per recurrence-free year.
How long does BCG treatment last?
The initial BCG cancer treatment occurs weekly for six weeks. This is called induction therapy. If the treatment is working, your doctor may prescribe BCG maintenance therapy. Maintenance therapy is given once a week for three weeks at the three-, six- and 12-month marks.
Join TheMoney.co community and don’t forget to share this post !
